ArriVent BioPharma, Inc. (AVBP)
(Delayed Data from NSDQ)
$16.90 USD
-0.49 (-2.82%)
Updated Aug 12, 2025 03:59 PM ET
After-Market: $16.94 +0.04 (0.24%) 4:28 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AVBP 16.90 -0.49(-2.82%)
Will AVBP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVBP
New Strong Sell Stocks for July 21st
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
AVBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength
Other News for AVBP
HC Wainwright & Co. Raises Price Target for AVBP to $42 | AVBP Stock News
Citigroup Lowers Price Target for ArriVent BioPharma (AVBP) while Maintaining 'Buy' Rating | ...
ArriVent Biopharma price target raised by $2 at H.C. Wainwright, here's why
ArriVent Biopharma price target lowered by $7 at Citi, here's why
ArriVent BioPharma Reports Second Quarter 2025 Financial Results | AVBP Stock News